DarioHealth

DarioHealth AAQS

The The AAQS of DarioHealth (DRIO) as of Nov 3, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

DarioHealth has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock DarioHealth in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The DarioHealth AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
4.00 USD
Jan 1, 2019
4.00 USD
Jan 1, 2020
4.00 USD
Jan 1, 2021
4.00 USD
Jan 1, 2022
4.00 USD
Jan 1, 2023
4.00 USD
Jan 1, 2024
4.00 USD
Jan 1, 2025
4.00 USD
The DarioHealth AAQS history
YEARAAQSYoY
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
4—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DarioHealth Stock analysis

What does DarioHealth do? DarioHealth Corp. generates revenue through its digital therapeutics products, including the Dario Blood Glucose Monitoring System and the Dario Smart Diabetes Management Solution, sold via smartphone applications. These products are available on online marketplaces such as Amazon, Walmart, Best Buy, Google, and Apple app stores, targeting consumers directly. The DarioEngage platform offers real-time connectivity between users and caregivers, while Dario Intelligence provides analytics tools for healthcare providers to enhance treatment predictability. The company focuses on delivering integrated digital interventions at the intersection of life sciences, behavioral science, and software technology. DarioHealth's primary buyers are consumers seeking diabetes management solutions through direct-to-consumer channels. The company leverages partnerships with major retailers and app stores to reach its target audience, emphasizing user-centered design and evidence-based reporting. Its services are designed to support both individual users and healthcare providers through data-driven insights and engagement tools. The Dario Blood Glucose Monitoring System and Dario Smart Diabetes Management Solution form the core of DarioHealth's product offerings, delivered through mobile applications. These solutions integrate behavioral science with software technology to provide continuous support for diabetes management. The DarioEngage platform facilitates two-way communication, and Dario Intelligence assists healthcare providers in treatment planning and disease prediction, creating a comprehensive ecosystem for diabetes care. DarioHealth is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DarioHealth stock

The AAQS of DarioHealth is 4 in 2025.

On Eulerpool you can find the complete historical development of The AAQS DarioHealth since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — DarioHealth

All Key Metrics — DarioHealth